Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis (OASIS-C)

NCT07886775 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-11-01
Last updated
2026-10-21

Condition(s) studied

Carotid Stenosis

Investigational drug(s) / intervention(s)

OCT guided endovascular treatment

OCT guided endovascular treatment: OCT guides carotid balloon angioplasty and/or stenting of the target artery.

Study summary

Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis (OASIS-C) is a multicenter, prospective, exploratory trial using optical coherence tomography to guide endovascular treatment of carotid stenosis.

Eligibility

Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 20-80 years old. 2. Primary or recurrent symptomatic extracranial carotid artery stenosis (a recent TIA\[\<180 days\] or ischemic stroke \[14-180 days\] before enrollment attributed to 50-99% stenosis of extracranial carotid artery) receiving treatment with at least one antithrombotic drug and/or standard medical management of vascular risk factors. 3. Diagnosed by DSA: an extracranial carotid artery stenosis (50-99% according to NASCET method) with lesion length ≤ 10mm, diameter ≥ 1.5mm, and normal distal artery. (Regarding the curvature and angle of the lesion, whether the patient is enrolled per the investigator's determination based on the patient's situation ). 4. Informed consent signed. Exclusion Criteria: 1. Acute ischemic stroke onset within 14 days before enrollment. 2. Neurological deficits worsen within 24 hours before enrollment. 3. Baseline modified Rankin Scale ≥ 3. 4. Thrombolytic therapy within 24 hours before enrollment. 5. Previous ipsilateral endovascular treatment. 6. Intracranial hemorrhage within the past 3 months. 7. Any major surgery, major trauma, revascularization procedure, or acute coronary syndrome within 1 month before enrollment. 8. Major (non-carotid) surgery/procedures planned within 3 months after enrollment. 9. Gastrointestinal hemorrhage within 1 month prior to enrollment. 10. Allergic to heparin, aspirin, clopidogrel, contrast agents, anesthetics, and balloon components. 11. Platelet count \< 100,000/microliter or history of heparin-induced thrombocytopenia. 12. Severe dysfunction of liver (ALT \> three-fold higher than the upper limit of normal value or AST \> three-fold higher than the upper limit of normal value) or kidney (serum creatinine \> two-fold higher than the upper limit of normal value). 13. Non-atherosclerotic carotid stenosis (dissection, fibromuscular dysplasia, or stenosis following radiation therapy). 14. Intracranial arteries, target artery's supplying artery or contralateral carotid artery with 50-99% stenosis. 15. Coexistent with Intracranial tumors, aneurysms or arteriovenous malformations. 16. Tortuous vascular approach that cannot be stabilized to obtain vascular access. 17. Pregnant and lactating women. 18. Expected survival expectation is less than \< 6 months.

Primary outcome measure(s)

  • Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months — 6 months
    This outcome includes ischemic/hemorrhagic stroke or all-cause death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months.

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07886775 on ClinicalTrials.gov ↗ ← All trials in China